In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Determination and management of a PAD patient's need for surgery

An article from the e-journal of the ESC Council for Cardiology Practice

Pre-operative cardiac assessment of a peripheral artery disease patient is a common consultation request for the cardiologist. Read an update here on how to see this process through. 

Peripheral Arterial Diseases


Background

Awareness that cardiovascular disease is a leading cause of premature death, most often manifested as coronary artery disease - is spreading. (1,2)
Awareness that peripheral arterial disease (PAD) - defined as an ankle-brachial ratio of 0.9 or when patient has been previously revascularised with surgery or transluminal angioplasty - is a significant health burden however is not, even though 10% of the general population, 20% of those above 70 years and 30% of diabetics over 50 have PAD. (3,4) 
During surgery, these patients are at double the risk of cardiovascular mortality and major artery coronary events (MACE) because PAD usually comes with CAD, and vice versa. Indeed the systemic atherosclerotic process is the most common aetiology for both PAD and CAD. (5)
Endovascular therapy angioplasty also incurs a high risk of adverse cardiovascular outcome. 
Pre-operative identification and treatment of cardiovascular risk factors is vital to reduce this risk; through. Appropriate interventions, investigations and drugs are detailed here.

1 - Interventions

Peripheral artery disease affects areas of the vascular bed: the carotid, lower extremity - these two being the most common - the upper limb, mesenteric or renal arteries. Whatever the area, the presence of PAD in one territory should prompt investigation for PAD elsewhere and also trigger a search for CAD (6).
The vascular surgeon, at times with the interventional radiologist, will make the determination of each individual case according to the following framework for intervention:

  • Carotid endarterectomy - or endovascular carotid stenting in higher-risk patients - is recommended or considered in patients with:
    A - Symptomatic carotid artery disease, recent stroke/TIA (<6 months) and >70% stenosis in the internal carotid artery, ideally also within 2 weeks of symptom onset).
    B - Symptomatic patients with 50-69% stenosis
    C - Asymptomatic patients with 60-99% stenosis. 
  • Bypass surgery or endovascular intervention following an unsuccessful trial of risk factor control and medical therapy with aspirin and a statin. 
  • Endovascular therapy based on imaging for chronic lower extremity disease usually manifesting as intermittent claudication often with concomitant CAD.

The cardiologist should assess abnormal angiograms (in one study over 90% of patients with PAD had abnormal angiograms) and should assess: (7)

  1. Perioperative risk of cardiovascular adverse events - mortality, myocardial infarction, pulmonary oedema, ventricular arrhythmia and relevant future long-term cardiovascular prognosis. 
  2. Clinical features in the patient's history which might suggest underlying CAD, including anginal symptoms, dyspnoea, risk factors (diabetes, hypertension, hyperlipidaemia, smoking, family history).
  3. Adverse signs on clinical examination (evidence of pulmonary congestion, cardiac murmurs etc.
    Standard 12-lead ECG should be obtained in all patients (class IB recommendation).
  4. Resting ECG abnormalities: they are predictive of cardiovascular mortality. (8)

The following conditions should be immediately dealt with prior to any or further PAD surgery:

  • Unstable cardiac conditions (acute coronary syndrome, decompensated heart failure or significant valvular heart disease for example) or clinical features suggestive of CAD based on clinical history, examination and resting ECG.


If however, there are no concerning features based on these initial screening tests, we recommend that the patient proceed to surgery as planned with no further evaluation.

Fig.1 Management flowchart for PAD patients referred for pre-operative cardiovascular assessment.

 

2 - Investigations

According to the 2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management, routine echocardiography and or functional testing is recommended only if patient has at least two among the following risk factors: Ischemic heart disease, heart failure, stroke or transient ischemic stroke, renal dysfunction or diabetes requiring insulin therapy.

Echocardiography

Pre-operative resting echocardiography can identify 1) significant valvular lesions and/or 2) severe left ventricular dysfunction in patients with:

  • A cardiac murmur or a sign of heart failure
  • High-risk and no symptoms (class IIa recommendation, level C). (9) 


Functional testing 

Exercise ECG

In patients in whom history is suggestive of angina, exercise treadmill testing (ETT) is a first-line screening tool for assessment of ischemia. Indeed, in a group of patients due to undergo vascular surgery, ETT showed acceptable diagnostic accuracy, similar to that of the general population (sensitivity 74%, specificity 69%). (10)
However stress echocardiography, nuclear imaging or stress CMR (see below), depending on availability, would be recommended when 1) patients with limited exercise tolerance due to limb claudication are unable to reach optimal exercise stress 2) resting ECG abnormalities cause difficulty in ETT interpretation.

Stress echocardiography

Stress echocardiography is most commonly administered using dobutamine or dipyridamole given the limited exercise tolerance of patients with PAD.
Extremely good prognosis is signaled if it is negative. The presence of an inducible wall motion abnormality is a relatively poor predictor of peri-operative MACE (positive predictive value 25-45%). In this group of patients, dobutamine may have a slightly higher sensitivity than dipyridamole.

Nuclear imaging

Nuclear scintigraphy is well validated as a pre-operative risk stratification tool in patients with PAD. Its predictive power is similar to dipyridamole stress echocardiography. (11)
As with stress echocardiography, the negative predictive value of nuclear imaging is extremely high.

Stress cardiovascular magnetic resonance

Stress magnetic resonance imaging using dobutamine or adenosine has excellent diagnostic accuracy for identification of significant ischaemia, however there are not any data as yet on its value in pre-operative risk stratification.

Computerised tomography coronary angiography


Multislice computerised tomography (MDCT) coronary angiography defines coronary anatomy non-invasively. Its sensitivity for diagnosis of significant coronary stenoses is very high and may be useful in patients with inconclusive functional stress tests. (12, 13) Nevertheless, given the prevalence of CAD in patients with PAD, these patients often have a higher pre-test probability. Current ESC guidelines for investigation of stable angina recommend coronary CT in patients with 15-50% (i.e. low-intermediate) pre-test probability. (14) Despite this, the absence of significant stenosis seen using coronary CT has been shown to have good prognostic value in predicting peri-operative mortality in patients at intermediate risk but has not yet been evaluated in a high-risk cohort.

Invasive coronary angiography

Current guidance recommends pre-operative invasive coronary angiography in patients with PAD and acute coronary syndromes or angina despite optimal medical therapy i.e. similar to current indications in the general population.
In high-risk patients without any cardiac symptoms, pre-operative invasive coronary angiography is one option, however this should not delay any urgent PAD surgery, which should always be carried out first. It is important to note that there is, at best, conflicting evidence to suggest any mortality benefit with a routine pre-operative invasive strategy. (15-17) Furthermore, the requirement of dual anti-platelet therapy post-stenting may delay surgery, which may not be ideal.
In our opinion, patients with a clear history of angina and documented ischaemia or CT evidence of severe stenosis should undergo pre-operative angiography with a view to percutaneous coronary intervention. We would not recommend routine angiography of asymptomatic patients without documented ischemia.

3 - Drugs

Beta-blockers

Among the most studied group of drugs in this area are beta-blockers. Until 2011, the guidelines were clear – beta-blockers, initiated between 7 to 30 days prior to operation in patients undergoing PAD surgery.
The DECREASE trial drove the evidence for this strategy, the methods of which have been called into question since and have lead both the ESC and the American societies to rewrite their guidelines. (18)
A meta-analysis published in 2011 without the DECREASE trials suggests that while pre-operative beta-blockers may reduce risk of non-fatal MI (by 27%), there was a 27% increase in all-cause mortality, and higher risk of stroke and hypotension. (19) The ESC has since recommended an individualised approach to pre-operative beta-blockade over routine and the latest guidelines advocate their use only when there are other indications, such as heart failure of ischaemic coronary disease. We would add that most patients should not routinely receive a beta-blocker and normal cardiological indications should be followed for patients with reduced left ventricular ejection fraction, atrial fibrillation with a fast ventricular rate and stable angina.

Other drugs

Pre-operative statins are recommended. (20-22) These should also be continued during the operative period to avoid a rebound effect that can occur with their discontinuation.
ACE-inhibitors (or angiotensin receptor antagonists) should be started in patients noted to have left ventricular systolic dysfunction pre-operatively (and surgery delayed to allow their initiation, if possible).
The key point regarding any other drugs is that the patient’s pre-operative regime should be continued during the operative period. 

Conclusions

Patients undergoing surgery for PAD are at high risk of peri-operative adverse cardiac events, primarily due to the systemic atherosclerotic process.

  1. All patients should undergo detailed clinical history taking, examination and resting ECG to determine baseline cardiac risk. 
  2. Further investigation and management should be directed based on this initial evaluation. Our suggestion for management is summarised in figure 1. 
  3. In asymptomatic patients with no significant ECG abnormalities, no further investigation is required and they can proceed to surgery. 
  4. Patients with unstable cardiac conditions such as MI or heart failure should have these dealt with immediately. 
  5. In other patients, it is important to continue routine pre-operative cardiac medications, with initiation of statins for those suspected to have some cardiovascular risk (in practice, essentially all patients with PAD) and ACE inhibitors and beta-blockers in those with reduced left ventricular function. 
  6. Evidence for routine use of pre-operative beta-blockers in all patients is inconclusive.

References


1 - European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)
Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F.. Eur Heart J 2012;33(13):1635-701.
2 - Effect of statin withdrawal on frequency of cardiac events after vascular surgery
Schouten O, Hoeks SE, Welten GM, Davignon J, Kastelein JJ, Vidakovic R, Feringa HH, Dunkelgrun M, van Domburg RT, Bax JJ, Poldermans D. Am J Cardiol 2007;100(2):316-20.
3 - Epidemiology, classification, and modifiable risk factors of peripheral arterial disease.
Shammas NW.  Vasc Health Risk Manag 2007;3(2):229-34.
4 - One-year cardiovascular event rates in outpatients with atherothrombosis.
Steg PG, Bhatt DL, Wilson PW, D'Agostino R, Sr., Ohman EM, Rother J, Liau CS, Hirsch AT, Mas JL, Ikeda Y, Pencina MJ, Goto S.  JAMA 2007;297(11):1197-206.
5 - Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis
Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Fowkes FG, Lee AJ, Price JF, d'Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodriguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM. . JAMA 2008;300(2):197-208.
6 - ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC).
Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Rother J, Sievert H, van Sambeek M, Zeller T. Eur Heart J 2011;32(22):2851-906.
7 - A classification of 1000 coronary angiograms and results of surgical management. 
Hertzer NR, Beven EG, Young JR, O'Hara PJ, Ruschhaupt WF, 3rd, Graor RA, Dewolfe VG, Maljovec LC. Coronary artery disease in peripheral vascular patients. Ann Surg 1984;199(2):223-33.
8 - Long-term prognostic value of the preoperative 12-lead electrocardiogram before major noncardiac surgery in coronary artery disease.
Jeger RV, Probst C, Arsenic R, Lippuner T, Pfisterer ME, Seeberger MD, Filipovic M.  Am Heart J 2006;151(2):508-13.
9 - Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery
Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Iung B, Kelm M, Kjeldsen KP, Kristensen SD, Lopez-Sendon J, Pelosi P, Philippe F, Pierard L, Ponikowski P, Schmid JP, Sellevold OF, Sicari R, Van den Berghe G, Vermassen F. Eur Heart J 2009;30(22):2769-812.
10 - A meta-analysis comparing the prognostic accuracy of six diagnostic tests for predicting perioperative cardiac risk in patients undergoing major vascular surgery
Kertai MD, Boersma E, Bax JJ, Heijenbrok-Kal MH, Hunink MG, L'Talien G J, Roelandt JR, van Urk H, Poldermans D. . Heart 2003;89(11):1327-34.
11 - Meta-analysis of intravenous dipyridamole-thallium-201 imaging (1985 to 1994) and dobutamine echocardiography (1991 to 1994) for risk stratification before vascular surgeryShaw LJ, Eagle KA, Gersh BJ, Miller DD. . J Am Coll Cardiol 1996;27(4):787-98.
12 - Prognostic value of CT angiography in patients with inconclusive functional stress tests
de Azevedo CF, Hadlich MS, Bezerra SG, Petriz JL, Alves RR, de Souza O, Rati M, Albuquerque DC, Moll J. . JACC Cardiovasc Imaging 2011;4(7):740-51.
13 - Selecting a noninvasive imaging study after an inconclusive exercise test
Blankstein R, Devore AD. Circulation 2010;122(15):1514-8.
14 - 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of CardiologyMontalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Knuuti J, Valgimigli M, Bueno H, Claeys MJ, Donner-Banzhoff N, Erol C, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, Hasdai D, Husted S, James SK, Kervinen K, Kolh P, Kristensen SD, Lancellotti P, Maggioni AP, Piepoli MF, Pries AR, Romeo F, Ryden L, Simoons ML, Sirnes PA, Steg PG, Timmis A, Wijns W, Windecker S, Yildirir A, Zamorano JL. . Eur Heart J 2013;34(38):2949-3003.
15 - Systematic strategy of prophylactic coronary angiography improves long-term outcome after major vascular surgery in medium- to high-risk patients: a prospective, randomized study
Monaco M, Stassano P, Di Tommaso L, Pepino P, Giordano A, Pinna GB, Iannelli G, Ambrosio G. J Am Coll Cardiol 2009;54(11):989-96.
16 - A clinical randomized trial to evaluate the safety of a noninvasive approach in high-risk patients undergoing major vascular surgery: the DECREASE-V Pilot Study
Poldermans D, Schouten O, Vidakovic R, Bax JJ, Thomson IR, Hoeks SE, Feringa HH, Dunkelgrun M, de Jaegere P, Maat A, van Sambeek MR, Kertai MD, Boersma E. J Am Coll Cardiol 2007;49(17):1763-9.
17 - Coronary-artery revascularization before elective major vascular surgery.
McFalls EO, Ward HB, Moritz TE, Goldman S, Krupski WC, Littooy F, Pierpont G, Santilli S, Rapp J, Hattler B, Shunk K, Jaenicke C, Thottapurathu L, Ellis N, Reda DJ, Henderson WG.  N Engl J Med 2004;351(27):2795-804.
18 - The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery
Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999;341(24):1789-94.
19 - Meta-analysis of secure randomised controlled trials of beta-blockade to prevent perioperative death in non-cardiac surgery
Bouri S, Shun-Shin MJ, Cole GD, Mayet J, Francis DP.. Heart 2014;100(6):456-64.
20 - Effect of perioperative statins on death, myocardial infarction, atrial fibrillation, and length of stay: a systematic review and meta-analsis
Chopra V, Wesorick DH, Sussman JB, Greene T, Rogers M, Froehlich JB, Eagle KA, Saint S. s. Arch Surg 2012;147(2):181-9.
21 - Evidence of pre-procedural statin therapy a meta-analysis of randomized trials
Winchester DE, Wen X, Xie L, Bavry AA. J Am Coll Cardiol 2010;56(14):1099-109.
22 - New ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management.
Kristensen SD, Knuuti J. Eur Heart J. 2014 Sep 14;35(35):2344-5. doi: 10.1093/eurheartj/ehu285. Epub 2014 Aug 7.

Notes to editor


Ify Mordi, Nikolaos Tzemos
BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, United KingdomAddress for Correspondence:
Dr Nikolaos Tzemos
Institute of Cardiovascular and Medical Sciences
British Heart Foundation Glasgow Cardiovascular Research Centre
University of Glasgow
Glasgow
United Kingdom
G12 8TA
E-mail: niko.tzemos@glasgow.ac.uk
Telephone: +44(0)141 330 2079
Fax: +44(0)141 330 6697

Authors' Disclosures: None declared.

Other ressources in PAD
PAD is a coronary heart disease risk equivalent in women as it is in men (2014)
Aspirin use, still first-line (2013)
Is PAD uncommon in women? (2012)

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.